XTEN Polypeptide Conjugates for Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for extending the half-life of therapeutic agents, such as pegylation, face challenges including high costs, complex manufacturing processes, and low purity of final products, along with potential severe side effects due to metabolite accumulation and antibody induction.
Innovation Solution
Development of substantially homogeneous extended recombinant polypeptides (XTEN) that can be purified easily and used for conjugation with payload peptides or proteins, offering high-yield, high-purity, and stable XTEN-linked agents with enhanced pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If pegylation is used to extend half-life of therapeutic agents, then the half-life is extended, but the manufacturing complexity increases and product purity decreases
Solution Approach 1:
The invention changes the chemical structure parameter by using XTEN polypeptides with specific amino acid compositions (high content of G, A, S, T, E, and P residues) and controlled molecular weights (36-3000 residues) to achieve half-life extension while maintaining manufacturing simplicity and product homogeneity
Solution Approach 2:
The invention creates composite therapeutic agents by conjugating payload molecules to XTEN polypeptides, forming homogeneous XTEN-payload conjugates that combine the pharmacological activity of the payload with the extended circulation half-life of XTEN
2Duration of action of stationary object
If pegylation is used to extend half-life of therapeutic agents, then the half-life is extended, but the production cost increases
Solution Approach 1:
The invention optimizes the molecular weight parameter of XTEN polypeptides (36-3000 amino acid residues) to achieve effective half-life extension while controlling production costs through efficient expression and purification systems
Solution Approach 2:
The XTEN polypeptides are produced through recombinant expression systems that enable large-scale production, and the purified XTEN serves as a stable platform for conjugation with various payloads, reducing overall manufacturing costs
3Duration of action of stationary object
If pegylation is used to extend half-life of therapeutic agents, then the half-life is extended, but the product homogeneity decreases
Solution Approach 1:
The invention achieves product homogeneity by producing XTEN polypeptides with uniform amino acid compositions and controlled molecular weights through recombinant expression, ensuring that all XTEN molecules in the conjugate population are identical in structure and properties
Solution Approach 2:
The invention controls the molecular weight parameter of XTEN (36-3000 residues) to achieve the desired balance between half-life extension and product homogeneity, with narrower molecular weight distributions compared to PEGylated agents
4Duration of action of stationary object
If PEGylated proteins are used for half-life extension, then the half-life is extended, but severe side effects occur due to metabolite accumulation and antibody induction
Solution Approach 1:
The invention extracts the harmful PEG component from the half-life extension strategy and replaces it with XTEN polypeptides that provide the same pharmacokinetic benefits without the adverse effects of metabolite accumulation and anti-PEG antibody induction
Solution Approach 2:
The invention converts the biocompatible and biodegradable properties of XTEN polypeptides into therapeutic benefit, where the natural amino acid composition ensures safe metabolism without the harmful effects associated with PEGylated agents
Data Source
AI summary
The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.